Goldman Sachs’s AbbVie ABBV Stock Holding History

Goldman Sachs’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$163M	Buy	750,900 +210,200	+39%	+$46.6M	0.02%	774
2025 Q4	$124M	Buy	540,700 +229,500	+74%	+$52.3M	0.02%	869
2025 Q3	$72.1M	Sell	311,200 -48,100	-13%	-$9.8M	0.01%	1151
2025 Q2	$66.7M	Buy	359,300 +74,200	+26%	+$13.8M	0.01%	1153
2025 Q1	$59.7M	Buy	285,100 +3,400	+1%	+$661K	0.01%	1121
2024 Q4	$50.1M	Sell	281,700 -82,600	-23%	-$15.2M	0.01%	1287
2024 Q3	$71.9M	Buy	364,300 +17,000	+5%	+$3.17M	0.01%	974
2024 Q2	$59.6M	Sell	347,300 -3,900	-1%	-$646K	0.01%	1045
2024 Q1	$64M	Sell	351,200 -17,600	-5%	-$3.03M	0.01%	1016
2023 Q4	$57.2M	Sell	368,800 -178,800	-33%	-$26.1M	0.01%	1095
2023 Q3	$81.6M	Buy	547,600 +59,500	+12%	+$8.73M	0.02%	818
2023 Q2	$65.8M	Buy	488,100 +231,100	+90%	+$33.9M	0.01%	923
2023 Q1	$41M	Sell	257,000 -32,600	-11%	-$4.98M	0.01%	1211
2022 Q4	$46.8M	Buy	289,600 +83,000	+40%	+$12.7M	0.01%	1232
2022 Q3	$27.7M	Sell	206,600 -54,600	-21%	-$7.84M	0.01%	1581
2022 Q2	$40M	Buy	261,200 +31,700	+14%	+$4.84M	0.01%	1283
2022 Q1	$37.2M	Sell	229,500 -346,300	-60%	-$50.3M	0.01%	1550
2021 Q4	$78M	Buy	575,800 +53,500	+10%	+$6.32M	0.02%	971
2021 Q3	$56.3M	Sell	522,300 -50,400	-9%	-$5.76M	0.01%	1200
2021 Q2	$64.5M	Buy	572,700 +103,800	+22%	+$11.7M	0.01%	1053
2021 Q1	$50.7M	Sell	468,900 -455,300	-49%	-$48.7M	0.01%	1161
2020 Q4	$99M	Buy	924,200 +531,100	+135%	+$51M	0.03%	623
2020 Q3	$34.4M	Buy	393,100 +141,600	+56%	+$13.3M	0.01%	1294
2020 Q2	$24.7M	Sell	251,500 -129,000	-34%	-$11.4M	0.01%	1510
2020 Q1	$29M	Sell	380,500 -287,200	-43%	-$24.5M	0.01%	1240
2019 Q4	$59.1M	Buy	667,700 +73,400	+12%	+$6.09M	0.02%	1023
2019 Q3	$45M	Buy	594,300 +59,200	+11%	+$4.06M	0.01%	1178
2019 Q2	$38.9M	Buy	535,100 +294,400	+122%	+$23.1M	0.01%	1336
2019 Q1	$19.4M	Sell	240,700 -109,400	-31%	-$8.95M	0.01%	1900
2018 Q4	$32.3M	Buy	350,100 +279,700	+397%	+$24.6M	0.01%	1423
2018 Q3	$6.66M	Sell	70,400 -12,200	-15%	-$1.16M	﹤0.01%	2768
2018 Q2	$7.65M	Sell	82,600 -65,200	-44%	-$6.37M	﹤0.01%	2627
2018 Q1	$14M	Sell	147,800 -187,800	-56%	-$20.6M	﹤0.01%	2096
2017 Q4	$32.5M	Sell	335,600 -85,300	-20%	-$8.04M	0.01%	1593
2017 Q3	$37.4M	Buy	420,900 +89,600	+27%	+$6.82M	0.01%	1491
2017 Q2	$24M	Sell	331,300 -192,800	-37%	-$13M	0.01%	1794
2017 Q1	$34.1M	Sell	524,100 -74,200	-12%	-$4.66M	0.01%	1492
2016 Q4	$37.5M	Sell	598,300 -139,100	-19%	-$8.49M	0.01%	1472
2016 Q3	$46.5M	Sell	737,400 -51,400	-7%	-$3.33M	0.01%	1263
2016 Q2	$48.8M	Buy	788,800 +591,500	+300%	+$36M	0.02%	1134
2016 Q1	$11.3M	Sell	197,300 -816,008	-81%	-$45.5M	﹤0.01%	2127
2015 Q4	$60M	Sell	1,013,308 -257,900	-20%	-$14.9M	0.02%	985
2015 Q3	$69.2M	Sell	1,271,208 -656,000	-34%	-$42.7M	0.02%	843
2015 Q2	$129M	Buy	1,927,208 +1,387,508	+257%	+$90.6M	0.04%	521
2015 Q1	$31.6M	Sell	539,700 -451,300	-46%	-$27.3M	0.01%	1436
2014 Q4	$64.9M	Buy	991,000 +503,500	+103%	+$31.7M	0.02%	923
2014 Q3	$28.2M	Buy	487,500 +476,000	+4,139%	+$26.4M	0.01%	1533
2014 Q2	$649K	Sell	11,500 -230,100	-95%	-$12.1M	﹤0.01%	5094
2014 Q1	$12.4M	Sell	241,600 -362,800	-60%	-$18.3M	﹤0.01%	2171
2013 Q4	$31.9M	Buy	604,400 +420,500	+229%	+$20.7M	0.01%	1397
2013 Q3	$8.23M	Sell	183,900 -20,100	-10%	-$891K	﹤0.01%	2433
2013 Q2	$8.43M	Buy	+204,000	New	+$8.92M	﹤0.01%	2231

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's ABBV Position: Q1 2026 in Review

Goldman Sachs increased its AbbVie (ABBV) stake by 17% in Q1 2026, buying an estimated $477M and bringing the position to 15,145,279 shares worth $3.29B. The position accounts for 0.38% of the portfolio, ranked #28.

Goldman Sachs first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Goldman Sachs held 15,145,279 shares of AbbVie worth $3.29B as of Q1 2026.
Goldman Sachs bought 2,149,654 AbbVie shares in Q1 2026, an estimated $477M.
AbbVie made up 0.38% of Goldman Sachs's portfolio in Q1 2026, its #28 holding.
Goldman Sachs first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.